WASHINGTON, D.C. — In response to the Senate Finance Committee releasing its packaged proposal on prescription drug prices, Adam Brandon, FreedomWorks President, had the following statement:
“We are sorely disappointed that the Senate Finance Committee has released a proposal that includes an inflationary penalty for drug manufacturers in Medicare Part D. This measure is nothing less than a form of price controls and will have adverse impacts on innovation and drug supply in the near future.
“The release of this package is especially upsetting given that Chairman Grassley has correctly acknowledged that price controls are the wrong way to go about lowering drug prices. It is sad to see Chairman Grassley now cave to Democrats on the committee and introduce a proposal which includes price controls that would be just as harmful to patients and caregivers across the nation as those he previously opposed.
“We strongly urge other members of the committee and the Senate to come out and forcefully oppose any and all forms of drug price controls. We cannot afford to put our nation on the slippery slope towards socialized medicine.”
FreedomWorks Letter to Congress in Support of Fiscal Commision Act (H.R. 5779)